BCL2 and B-cell chronic lymphocytic leukemia: BH3 profiling assays on permeabilized CLL cells cannot readily distinguish the impact of targeting BCL2 with venetoclax from that of BH3 mimetic compounds targeting other pro-survival relatives of BCL2